Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.

Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R (2006)
Eur J Health Econ 7(4): 290-296.

Download
Es wurde kein Volltext hochgeladen. Nur Publikationsnachweis!
Zeitschriftenaufsatz | Veröffentlicht | Englisch
Autor
; ; ; ;
Abstract / Bemerkung
We carried out a cost-effectiveness evaluation of transdermal fentanyl compared to three other widely used opioids: transdermal buprenorphine, sustained-release morphine, and controlled-release oxycodone from a third-party-payers perspective. A decision analytic model with data from a structured database search and from panel data and assumptions was used to derive both cost and utility results. Probabilistic sensitivity analysis was performed to ensure the findings. Transdermal fentanyl patients gain more quality adjusted life-days or quality-adjusted life-years per euro. The incremental cost per quality-adjusted life-year is 1,625.65 euro for transdermal fentanyl compared to sustained-release morphine and 1,003.03 euro compared to CO, and it is cost-saving compared to transdermal buprenorphine (-203.38 euro per patient). Transdermal fentanyl is thus cost-effective compared to both sustained-release morphine and CO and dominant compared to transdermal buprenorphine in the treatment of adults with nonmalignant moderate to severe chronic pain.
Erscheinungsjahr
Zeitschriftentitel
Eur J Health Econ
Band
7
Zeitschriftennummer
4
Seite
290-296
ISSN
eISSN
PUB-ID

Zitieren

Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006;7(4):290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., & Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), 290-296. doi:10.1007/s10198-006-0376-8
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., and Sabatowski, R. (2006). Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ 7, 290-296.
Greiner, W., et al., 2006. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ, 7(4), p 290-296.
W. Greiner, et al., “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”, Eur J Health Econ, vol. 7, 2006, pp. 290-296.
Greiner, W., Lehmann, K., Earnshaw, S., Bug, C., Sabatowski, R.: Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 7, 290-296 (2006).
Greiner, Wolfgang, Lehmann, K, Earnshaw, S, Bug, C, and Sabatowski, R. “Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany.”. Eur J Health Econ 7.4 (2006): 290-296.

13 Zitationen in Europe PMC

Daten bereitgestellt von Europe PubMed Central.

Addressing the barriers related with opioid therapy for management of chronic pain in India.
Dureja GP, Jain PN, Joshi M, Saxena A, Das G, Ahdal J, Narang P., Pain Manag 7(4), 2017
PMID: 28699380
Economic evaluation in chronic pain: a systematic review and de novo flexible economic model.
Sullivan W, Hirst M, Beard S, Gladwell D, Fagnani F, López Bastida J, Phillips C, Dunlop WC., Eur J Health Econ 17(6), 2016
PMID: 26377997
Clinical simulation model of long-acting opioids for treatment of chronic non-cancer pain in the United States.
Neil N, Merchant S, Provenzano D, Ogden K, Mody SH., J Med Econ 16(2), 2013
PMID: 23216013
The cost-effectiveness of duloxetine in chronic low back pain: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Wohlreich MM, Klein RW, Happich M., Value Health 16(2), 2013
PMID: 23538186
Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain.
Merchant S, Noe LL, Howe A, Duff S, Gricar J, Ogden K, Mody SH., Clin Ther 35(5), 2013
PMID: 23587608
Cost-effectiveness of duloxetine in chronic low back pain: a Quebec societal perspective.
Wielage R, Bansal M, Wilson K, Klein R, Happich M., Spine (Phila Pa 1976) 38(11), 2013
PMID: 23250234
Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.
Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M., Appl Health Econ Health Policy 11(3), 2013
PMID: 23616247
Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach.
Hass B, Lungershausen J, Hertel N, Poulsen Nautrup B, Kotowa W, Liedgens H., Eur J Health Econ 10(3), 2009
PMID: 19101743
Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H, Hertel N, Gabriel A, Nuijten M, Dakin H, Mitchell S, Nautrup BP., Clin Drug Investig 28(9), 2008
PMID: 18666805

37 References

Daten bereitgestellt von Europe PubMed Central.

Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain.
Allan L, Hays H, Jensen NH, de Waroux BL, Bolt M, Donald R, Kalso E., BMJ 322(7295), 2001
PMID: 11348910

AUTHOR UNKNOWN, 0
Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability.
Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A., Value Health 8(1), 2005
PMID: 15841890

AUTHOR UNKNOWN, 0

AUTHOR UNKNOWN, 0
Efficacy and safety of a once-daily morphine formulation in chronic, moderate-to-severe osteoarthritis pain: results from a randomized, placebo-controlled, double-blind trial and an open-label extension trial.
Caldwell JR, Rapoport RJ, Davis JC, Offenberg HL, Marker HW, Roth SH, Yuan W, Eliot L, Babul N, Lynch PM., J Pain Symptom Manage 23(4), 2002
PMID: 11997197
Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain.
Clark AJ, Ahmedzai SH, Allan LG, Camacho F, Horbay GL, Richarz U, Simpson K., Curr Med Res Opin 20(9), 2004
PMID: 15383190
A cost-utility analysis of the home parenteral nutrition program at Toronto General Hospital: 1970-1982.
Detsky AS, McLaughlin JR, Abrams HB, Whittaker JS, Whitwell J, L'Abbe K, Jeejeebhoy KN., JPEN J Parenter Enteral Nutr 10(1), 1986
PMID: 3080625
Predicting Quality of Well-being scores from the SF-36: results from the Beaver Dam Health Outcomes Study.
Fryback DG, Lawrence WF, Martin PA, Klein R, Klein BE., Med Decis Making 17(1), 1997
PMID: 8994146
Patient utilities in chronic musculoskeletal pain: how useful is the standard gamble method?
Goossens ME, Vlaeyen JW, Rutten-van Molken MP, van der Linden SM., Pain 80(1-2), 1999
PMID: 10204750
Efficacy and safety of controlled-release versus immediate-release oxycodone: randomized, double-blind evaluation in patients with chronic back pain.
Hale ME, Fleischmann R, Salzman R, Wild J, Iwan T, Swanton RE, Kaiko RF, Lacouture PG., Clin J Pain 15(3), 1999
PMID: 10524470
Prioritising elective care: a cost utility analysis of orthopaedics in the north west of England.
James M, St Leger S, Rowsell KV., J Epidemiol Community Health 50(2), 1996
PMID: 8762386
Recommendations for using opioids in chronic non-cancer pain.
Kalso E, Allan L, Dellemijn PL, Faura CC, Ilias WK, Jensen TS, Perrot S, Plaghki LH, Zenz M., Eur J Pain 7(5), 2003
PMID: 12935789

Maier, Dtsch Arztebl 99(), 2002
Cost-effectiveness of lumbar discectomy for the treatment of herniated intervertebral disc.
Malter AD, Larson EB, Urban N, Deyo RA., Spine 21(9), 1996
PMID: 8724089
Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain.
Milligan K, Lanteri-Minet M, Borchert K, Helmers H, Donald R, Kress HG, Adriaensen H, Moulin D, Jarvimaki V, Haazen L., J Pain 2(4), 2001
PMID: 14622817
Economic evaluation of the fentanyl transdermal system for the treatment of chronic moderate to severe pain.
Neighbors DM, Bell TJ, Wilson J, Dodd SL., J Pain Symptom Manage 21(2), 2001
PMID: 11226764

AUTHOR UNKNOWN, 0
Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Radbruch L, Sabatowski R, Loick G, Kulbe C, Kasper M, Grond S, Lehmann KA., Palliat Med 14(2), 2000
PMID: 10829145
Around-the-clock, controlled-release oxycodone therapy for osteoarthritis-related pain: placebo-controlled trial and long-term evaluation.
Roth SH, Fleischmann RM, Burch FX, Dietz F, Bockow B, Rapoport RJ, Rutstein J, Lacouture PG., Arch. Intern. Med. 160(6), 2000
PMID: 10737286
Can a controlled-release oral dose form of oxycodone be used as readily as an immediate-release form for the purpose of titrating to stable pain control?
Salzman RT, Roberts MS, Wild J, Fabian C, Reder RF, Goldenheim PD., J Pain Symptom Manage 18(4), 1999
PMID: 10534967
Utility assessments of opioid treatment for chronic pain.
Schmier JK, Palmer CS, Flood EM, Gourlay G., Pain Med 3(3), 2002
PMID: 15099257

AUTHOR UNKNOWN, 0
The impact of nausea and vomiting on women: a burden of early pregnancy.
Smith C, Crowther C, Beilby J, Dandeaux J., Aust N Z J Obstet Gynaecol 40(4), 2000
PMID: 11194422
Health-related quality of life and hand eczema--a comparison of two instruments, including factor analysis.
Wallenhammar LM, Nyfjall M, Lindberg M, Meding B., J. Invest. Dermatol. 122(6), 2004
PMID: 15175027

World, Cancer pain relief and palliative care(), 1990

AUTHOR UNKNOWN, 0

World, Cancer pain relief and palliative care(), 2004

Export

Markieren/ Markierung löschen
Markierte Publikationen

Open Data PUB

Quellen

PMID: 16983521
PubMed | Europe PMC

Suchen in

Google Scholar